The Genomic Landscape of Renal Oncocytoma Identifies a Metabolic Barrier to Tumorigenesis

Cell Reports

Volumn 13, Issue 9, 2015, Pages 1895-1908

  Joshi, Shilpy ^a   Tolkunov, Denis ^a   Aviv, Hana ^b   Hakimi, Abraham A ^c   Yao, Ming ^a   Hsieh, James J ^c   Ganesan, Shridar ^a,b   Chan, Chang S ^a,b   White, Eileen ^a,d  

^a RUTGERS CANCER INSTITUTE OF NEW JERSEY   (United States)

^b ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^d RUTGERS UNIVERSITY   (United States)

Author keywords

Cancer genomics; Cancer metabolism; Lysosome; Mitochondria; Oncocytoma

Indexed keywords

CYCLIN D1; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; PROTEIN P53; TRANSCRIPTOME; CATHEPSIN; CCND1 PROTEIN, HUMAN; LAMP1 PROTEIN, HUMAN; LYSOSOME ASSOCIATED MEMBRANE PROTEIN; METFORMIN;

ARTICLE; CARCINOGENESIS; CCND1 GENE; CELL CYCLE REGULATION; CLINICAL ARTICLE; CONTROLLED STUDY; COPY NUMBER VARIATION; ENZYME ACTIVATION; EOSINOPHIL; EXOME; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE MUTATION; GENE REARRANGEMENT; GENE SEQUENCE; GENETIC ASSOCIATION; HUMAN; HUMAN TISSUE; MITOCHONDRIAL GENOME; MITOPHAGY; ONCOCYTOMA; ONCOGENE; PRINCIPAL COMPONENT ANALYSIS; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN DEGRADATION; RENAL ONCOCYTOMA; SINGLE NUCLEOTIDE POLYMORPHISM; TUMOR GROWTH; AUTOPHAGY; CELL TRANSFORMATION; DRUG EFFECTS; FEMALE; GENETICS; GOLGI COMPLEX; KARYOTYPE; KIDNEY; KIDNEY CARCINOMA; KIDNEY TUMOR; LYSOSOME; MALE; METABOLISM; MITOCHONDRION; PATHOLOGY; SEQUENCE ANALYSIS;

ADENOMA, OXYPHILIC; AMP-ACTIVATED PROTEIN KINASES; AUTOPHAGY; CARCINOMA, RENAL CELL; CATHEPSINS; CELL TRANSFORMATION, NEOPLASTIC; CYCLIN D1; DNA COPY NUMBER VARIATIONS; FEMALE; GOLGI APPARATUS; HUMANS; KARYOTYPE; KIDNEY; KIDNEY NEOPLASMS; LYSOSOME-ASSOCIATED MEMBRANE GLYCOPROTEINS; LYSOSOMES; MALE; METFORMIN; MITOCHONDRIA; SEQUENCE ANALYSIS, RNA; TRANSCRIPTOME; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84947460214     PISSN: None     EISSN: 22111247     Source Type: Journal    
DOI: 10.1016/j.celrep.2015.10.059     Document Type: Article

References (40)

1. Bridges H.R., Jones A.J., Pollak M.N., Hirst J. Effects of metformin and other biguanides on oxidative phosphorylation in mitochondria. Biochem. J. 2014, 462:475-487.
2. Davis C.F., Ricketts C.J., Wang M., Yang L., Cherniack A.D., Shen H., Buhay C., Kang H., Kim S.C., Fahey C.C., et al. The somatic genomic landscape of chromophobe renal cell carcinoma. Cancer Cell 2014, 26:319-330. Cancer Genome Atlas Research Network.
3. Durinck S., Stawiski E.W., Pavia-Jimenez A., Modrusan Z., Kapur P., Jaiswal B.S., Zhang N., Toffessi-Tcheuyap V., Nguyen T.T., Pahuja K.B., et al. Spectrum of diverse genomic alterations define non-clear cell renal carcinoma subtypes. Nat. Genet. 2015, 47:13-21.
4. Ebersberger I., Metzler D., Schwarz C., Pääbo S. Genomewide comparison of DNA sequences between humans and chimpanzees. Am. J. Hum. Genet. 2002, 70:1490-1497.
5. Eskelinen E.L. Roles of LAMP-1 and LAMP-2 in lysosome biogenesis and autophagy. Mol. Aspects Med. 2006, 27:495-502.
6. Gao J., Aksoy B.A., Dogrusoz U., Dresdner G., Gross B., Sumer S.O., Sun Y., Jacobsen A., Sinha R., Larsson E., et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci. Signal. 2013, 6:pl1.
7. Gasparre G., Porcelli A.M., Bonora E., Pennisi L.F., Toller M., Iommarini L., Ghelli A., Moretti M., Betts C.M., Martinelli G.N., et al. Disruptive mitochondrial DNA mutations in complex I subunits are markers of oncocytic phenotype in thyroid tumors. Proc. Natl. Acad. Sci. USA 2007, 104:9001-9006.
8. Gasparre G., Hervouet E., de Laplanche E., Demont J., Pennisi L.F., Colombel M., Mège-Lechevallier F., Scoazec J.Y., Bonora E., Smeets R., et al. Clonal expansion of mutated mitochondrial DNA is associated with tumor formation and complex I deficiency in the benign renal oncocytoma. Hum. Mol. Genet. 2008, 17:986-995.
9. Gasparre G., Romeo G., Rugolo M., Porcelli A.M. Learning from oncocytic tumors: Why choose inefficient mitochondria?. Biochim. Biophys. Acta 2011, 1807:633-642.
10. Graef M., Nunnari J. Mitochondria regulate autophagy by conserved signalling pathways. EMBO J. 2011, 30:2101-2114.
11. Guo J.Y., Karsli-Uzunbas G., Mathew R., Aisner S.C., Kamphorst J.J., Strohecker A.M., Chen G., Price S., Lu W., Teng X., et al. Autophagy suppresses progression of K-ras-induced lung tumors to oncocytomas and maintains lipid homeostasis. Genes Dev. 2013, 27:1447-1461.
12. Guo J.Y., Xia B., White E. Autophagy-mediated tumor promotion. Cell 2013, 155:1216-1219.
13. Hudacko R., May M., Aviv H. A new translocation between chromosomes 6 and 9 helps to establish diagnosis of renal oncocytoma. Ann. Diagn. Pathol. 2011, 15:278-281.
14. Ishidoh K., Kominami E. Processing and activation of lysosomal proteinases. Biol. Chem. 2002, 383:1827-1831.
15. Ju Y.S., Alexandrov L.B., Gerstung M., Martincorena I., Nik-Zainal S., Ramakrishna M., Davies H.R., Papaemmanuil E., Gundem G., Shlien A., et al. Origins and functional consequences of somatic mitochondrial DNA mutations in human cancer. eLife 2014, 3:3. ICGC Breast Cancer Group, ICGC Chronic Myeloid Disorders GroupICGC Chronic Myeloid Disorders Group, ICGC Prostate Cancer GroupICGC Prostate Cancer Group.
16. Karsli-Uzunbas G., Guo J.Y., Price S., Teng X., Laddha S.V., Khor S., Kalaany N.Y., Jacks T., Chan C.S., Rabinowitz J.D., White E. Autophagy is required for glucose homeostasis and lung tumor maintenance. Cancer Discov. 2014, 4:914-927.
17. Kokoszka J.E., Waymire K.G., Levy S.E., Sligh J.E., Cai J., Jones D.P., MacGregor G.R., Wallace D.C. The ADP/ATP translocator is not essential for the mitochondrial permeability transition pore. Nature 2004, 427:461-465.
18. Linehan W.M., Ricketts C.J. The metabolic basis of kidney cancer. Semin. Cancer Biol. 2013, 23:46-55.
19. Mao L., Li N., Guo Y., Xu X., Gao L., Xu Y., Zhou L., Liu W. AMPK phosphorylates GBF1 for mitotic Golgi disassembly. J. Cell Sci. 2013, 126:1498-1505.
20. Mayr J.A., Meierhofer D., Zimmermann F., Feichtinger R., Kogler C., Ratschek M., Schmeller N., Sperl W., Kofler B. Loss of complex I due to mitochondrial DNA mutations in renal oncocytoma. Clin. Cancer Res. 2008, 14:2270-2275.
21. McBride H., Soubannier V. Mitochondrial function: OMA1 and OPA1, the grandmasters of mitochondrial health. Curr. Biol. 2010, 20:R274-R276.
22. Mishra P., Carelli V., Manfredi G., Chan D.C. Proteolytic cleavage of Opa1 stimulates mitochondrial inner membrane fusion and couples fusion to oxidative phosphorylation. Cell Metab. 2014, 19:630-641.
23. Miyamoto T., Oshiro N., Yoshino K., Nakashima A., Eguchi S., Takahashi M., Ono Y., Kikkawa U., Yonezawa K. AMP-activated protein kinase phosphorylates Golgi-specific brefeldin A resistance factor 1 at Thr1337 to induce disassembly of Golgi apparatus. J. Biol. Chem. 2008, 283:4430-4438.
24. Nabi I.R., Rodriguez-Boulan E. Increased LAMP-2 polylactosamine glycosylation is associated with its slower Golgi transit during establishment of a polarized MDCK epithelial monolayer. Mol. Biol. Cell 1993, 4:627-635.
25. Ng K.L., Rajandram R., Morais C., Yap N.Y., Samaratunga H., Gobe G.C., Wood S.T. Differentiation of oncocytoma from chromophobe renal cell carcinoma (RCC): can novel molecular biomarkers help solve an old problem?. J. Clin. Pathol. 2014, 67:97-104.
26. Pollak M. Potential applications for biguanides in oncology. J. Clin. Invest. 2013, 123:3693-3700.
27. Simonnet H., Demont J., Pfeiffer K., Guenaneche L., Bouvier R., Brandt U., Schagger H., Godinot C. Mitochondrial complex I is deficient in renal oncocytomas. Carcinogenesis 2003, 24:1461-1466.
28. Strohecker A.M., Guo J.Y., Karsli-Uzunbas G., Price S.M., Chen G.J., Mathew R., McMahon M., White E. Autophagy sustains mitochondrial glutamine metabolism and growth of BrafV600E-driven lung tumors. Cancer Discov. 2013, 3:1272-1285.
29. Sukov W.R., Ketterling R.P., Lager D.J., Carlson A.W., Sinnwell J.P., Chow G.K., Jenkins R.B., Cheville J.C. CCND1 rearrangements and cyclin D1 overexpression in renal oncocytomas: frequency, clinicopathologic features, and utility in differentiation from chromophobe renal cell carcinoma. Hum. Pathol. 2009, 40:1296-1303.
30. Tan A.S., Baty J.W., Dong L.F., Bezawork-Geleta A., Endaya B., Goodwin J., Bajzikova M., Kovarova J., Peterka M., Yan B., et al. Mitochondrial genome acquisition restores respiratory function and tumorigenic potential of cancer cells without mitochondrial DNA. Cell Metab. 2015, 21:81-94.
31. Tanaka Y., Guhde G., Suter A., Eskelinen E.L., Hartmann D., Lüllmann-Rauch R., Janssen P.M., Blanz J., von Figura K., Saftig P. Accumulation of autophagic vacuoles and cardiomyopathy in LAMP-2-deficient mice. Nature 2000, 406:902-906.
32. Thilly W.G. Have environmental mutagens caused oncomutations in people?. Nat. Genet. 2003, 34:255-259.
33. Vander Heiden M.G., Cantley L.C., Thompson C.B. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 2009, 324:1029-1033.
34. Varela I., Tarpey P., Raine K., Huang D., Ong C.K., Stephens P., Davies H., Jones D., Lin M.L., Teague J., et al. Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma. Nature 2011, 469:539-542.
35. Viale A., Pettazzoni P., Lyssiotis C.A., Ying H., Sánchez N., Marchesini M., Carugo A., Green T., Seth S., Giuliani V., et al. Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function. Nature 2014, 514:628-632.
36. Wallace D.C. Mitochondria and cancer. Nat. Rev. Cancer 2012, 12:685-698.
37. Warburg O. On respiratory impairment in cancer cells. Science 1956, 124:269-270.
38. Ward P.S., Thompson C.B. Metabolic reprogramming: a cancer hallmark even warburg did not anticipate. Cancer Cell 2012, 21:297-308.
39. Weinberg F., Hamanaka R., Wheaton W.W., Weinberg S., Joseph J., Lopez M., Kalyanaraman B., Mutlu G.M., Budinger G.R., Chandel N.S. Mitochondrial metabolism and ROS generation are essential for Kras-mediated tumorigenicity. Proc. Natl. Acad. Sci. USA 2010, 107:8788-8793.
40. Youle R.J., Narendra D.P. Mechanisms of mitophagy. Nat. Rev. Mol. Cell Biol. 2011, 12:9-14.